Very recently it has been demonstrated that utilizing the tumor‐penetrating abilities of dimeric IgA, intracellular mutated oncodrivers‐specific dimeric IgA antibodies could target and expel the oncoproteins out of PIGR+ cancer cells.27 The gene discussed is CD79A; the disease is cancer.